Licensing and supply agreement for JUXTAPIDLicensing Agreement • July 4th, 2024
Contract Type FiledJuly 4th, 2024Aegerion Pharmaceuticals has entered into an exclusive licensing agreement with Recordati Rare Diseases for the commercialization of JUXTAPID (lomitapide) in Japan.